Bioengineered Protein Drug Market size was valued at USD 111.3 billion in 2024 and is likely to cross USD 215.13 billion by 2037, registering more than 5.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of drone battery is assessed at USD 115.93 billion.. The growth of the market can be attributed to the increasing cases of cancer backed by the presence of multiple organizations to promote cancer treatment and the higher utilization of bioengineered proteins to provide relief in chemotherapy. According to the statistics of the World Health Organization (WHO), cancer is the second leading cause of death around the world. The statistics also stated that in the year 2018, cancer was responsible for an estimated 9.6 million deaths.
The prevalence of infectious diseases such as diabetes, cancer, and others is primarily increasing the global demand for bioengineered protein drugs. As opposed to alternative treatments for cancer, diabetes, and other illnesses, bioengineered protein medications are more successful and often have minimal or no side effects. As a result, healthcare practitioners are increasingly prescribing medicines that are made up of bioengineered protein drugs. Moreover, the escalating research and developments in bioengineered protein drugs and advancements in phase III clinical trials for the several medicines that are made from bioengineered protein drugs, are allowing pharmaceutical manufacturers to increasingly invest in the commercialization of this protein. The Centers for Disease Control and Prevention (CDC), in its statistical report “National Diabetes Statistics Report 2020”, stated that crude estimates for the prevalence of both diagnosed and undiagnosed diabetes amongst the US population aged 18 years or older in the year 2018 were registered to 34.1 million (10.5% of the US population).
Growth Drivers
Growing Prevalence of Cancer – cancer is the main disease that requires bioengineered protein drugs. These proteins are developed in labs to treat cancer cells and supply nutrient lines to nourish other tissues to fight cancer cells. Hence, it has a higher demand for chemotherapies across the globe. For instance, in 2020, approximately 10 million people died on account of cancer while in 2022, around 2 million new cases of cancer were diagnosed in the United States.
Rising Geriatric Population –According to the American Heart Association (AHA), the occurrence of Cardiovascular disease in men and women in the United States is 75% between the ages of 60 and 79, and 86% over the age of 80. Besides that, the National Health and Nutrition Examination Survey (NHANES) in the United States found that 70% of adults aged 65 and older have hypertension. The elderly population is more prone to get chronic diseases and the rising number of elderly populations across the globe is estimated to drive market growth.
Increasing Health Spending – The global health expenditure was anticipated to reach around USD 8.5 trillion in 2019 up from 8.5% in 2000. This boom in global health spending is expected to accelerate the development of bioengineered protein drugs over the forecast period.
Growing Incidences of Diabetes – diabetes is one of the most prevalent chronic diseases that can be treated with bioengineered protein drugs. For instance, around 500 million people across the globe were noticed to be living with diabetes in 2021.
Rising Cases of Asthma – for instance, in 2019, more than 250 million people were affected with asthma worldwide. On the other hand, around 3,500 people died on account of asthma in 2021 in US.
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.2% |
|
Base Year Market Size (2024) |
USD 111.3 billion |
|
Forecast Year Market Size (2037) |
USD 215.13 billion |
|
Regional Scope |
|
Drug Type (Recombinant Protein, Vaccine, Peptide Antibiotics, Therapeutic Enzymes)
The global bioengineered protein drug market is segmented and analyzed for demand and supply by drug type into recombinant protein, vaccine, peptide antibiotics, therapeutic enzymes, and others. Out of these types of drugs, the therapeutic enzymes segment is estimated to gain the largest market share in the year 2037. The growth of the segment can be attributed to the extensive use of therapeutic enzymes in the manufacturing of therapeutic proteins and the processing of recombinant DNA. Macromolecular therapeutic proteins, such as interferons, cytokines, and monoclonal antibodies, are extensively used in the treatment of HIV, cancer, and other diseases. A higher prevalence of HIV and cancer can be observed among the global population owing to several reasons such as rising tobacco and alcohol consumption, and others. For instance, it was estimated that nearly 8 million people lose their lives on account of tobacco consumption every year. Additionally, approximately 80% of tobacco users are observed to be living in developing countries.
Application (Autoimmune, Heart, Congenital, Infectious Diseases, Cancer, Diabetes, Arthritis)
The global bioengineered protein drug market is also segmented and analyzed for demand and supply by application into autoimmune, heart, congenital, infectious diseases, cancer, diabetes, arthritis, and others. Amongst these segments, the cancer segment is expected to garner a significant share in the year 2037. Cancer is the most common cause of mortality worldwide. Several types of antibodies are used to cure cancer such as monoclonal antibodies. These antibodies are cured in the labs to attack specific targets on cancer cells. Bioengineering cancer therapies include re-engineering tumor microenvironments to eliminate tumor-promoting cues and developing next-generation cell-based therapies. Furthermore, it was also observed in multiple studies that cancer patients require more protein than an ordinary healthy person. Since tumor kills the cell while bioengineered protein helps the tissues to fight infections. Some instances of the most suitable drugs for cancer are 5-fluorouracil, methotrexate, 6-mercaptopurine, gemcitabine, and cytarabine.
Our in-depth analysis of the global market includes the following segments:
|
By Drug Type |
|
|
By Application |
|
|
By Technology |
|
|
By Drug Delivery Method |
|
North American Market Forecast
The North America industry is estimated to dominate majority revenue share of by 2037. North America is known to have a strong network of drug companies. On the back of the increasing expenditure on healthcare, both by public and private entities, along with the increase in research and developmental activities and the prevalence of chronic diseases amongst individuals in the region, the North American bioengineered protein drug market is anticipated to grow at a rapid pace during the forecast period. For instance, in every 10 people in the United States, one of them has some sort of chronic disease such as diabetes, cancer, or heart disease. North America is known to have a very strong healthcare infrastructure present in the region which is also anticipated to boost the market growth over the forecast period.
APAC Market Statistics
The Asia Pacific bioengineered protein drug market, amongst the market in all the other regions, is projected to hold the second largest share during the forecast period. The growth of the market can be attributed majorly to the increasing instances of chronic diseases in the region backed by the boom in the population. Asia continent is known to have the largest population with a remarkable number of geriatrics. For instance, by the year 2050, there will be around 1 billion people aged 65 and above.
Europe Market Forecast
The European bioengineered protein drug market, amongst the market in all the other regions, is estimated to grow significantly till 2037. The growth of the market in the region can be accounted for a higher number of people living with diabetes in the region along with the presence of major bioengineered protein drug manufacturers. For instance, in 2022, nearly 20% of the population in the Europe region was anticipated to be aged 65 and above.
Abbott acquired St. Jude Medical, Inc., a medical device firm. The acquisition is expected to help Abbott Laboratories expand its market share in medical devices and improve its bio-engineered stent product range worldwide.
GlaxoSmithKline plc announced the retrospective study results on clinical trial diversity. The study included 495 GSK and ViiV clinical trials and was based on US participants.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?